bioRxiv preprint doi: https://doi.org/10.1101/2021.05.15.444275; this version posted June 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome Authors: Kirstin Mösbauer1,2#, Verena Nadin Fritsch3#, Lorenz Adrian4,5, Jörg Bernhardt6, Martin Clemens Horst Gruhlke7, Alan John Slusarenko7, Daniela Niemeyer1,2 and Haike Antelmann3* Departments & Institutions: 1Institute of Virology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, and Berlin Institute of Health (BIH), Charitéplatz 1, 10117, Berlin, Germany. 2German Centre for Infection Research (DZIF), Berlin, Germany. 3Freie Universität Berlin, Institute for Biology-Microbiology, D-14195 Berlin, Germany 4Department Environmental Biotechnology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany 5 Fachgebiet Geobiotechnologie, Technische Universität Berlin, Germany 6Institute for Microbiology, University of Greifswald, D-17489 Greifswald, Germany 7Department of Plant Physiology, RWTH Aachen University, 52056 Aachen, Germany Running title: Allicin inhibits replication of SARS-CoV-2 in Vero E6 and Calu-3 cells *Corresponding author: Haike Antelmann, Institute for Biology-Microbiology, Freie Universität Berlin, Königin-Luise-Strasse 12-16, D-14195 Berlin, Germany, Tel: +49-(0)30-838-51221, Fax: +49-(0)30-838-451221 E-mail:
[email protected] # Authors contributed equally to this work: Kirstin Mösbauer, Verena Nadin Fritsch Key words: SARS-CoV-2/ allicin/ Vero E6/ Calu-3/ proteome 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.15.444275; this version posted June 24, 2021.